Please login to the form below

Not currently logged in

US trial data shows Novavax’s COVID-19 vaccine is 90% effective

The jab was also found to provide protection against variants of concern and variants of interest

New data from a trial conducted in the US and Mexico has showed that Novavax’s COVID-19 vaccine NVX-CoV2373 is 90% effective at preventing COVID-19.

The phase 3 PREVENT-19 trial enrolled 29,960 participants across 119 sites in the US and Mexico to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373.

Overall, 63 COVID-18 cases were reported in the placebo group and 14 in the vaccine group, with all cases in the vaccinated group defined by trial protocol as mild. Meanwhile, ten moderate cases and four severe COVID-19 cases were observed in the placebo group.

As such, NVX-CoV2372 yielded a vaccine efficacy of 100% against moderate or severe COVID-19 infection.

In addition, the jab was found to provide protection against variants of concern (VoC) and variants of interest (VoI), with the B.1.17 variant – first discovered in the UK – becoming the predominant strain in the US during the accrual of the efficacy endpoints.

In a statement, Novavax said sequence data was available for 54 of the 77 COVID-19 cases observed in the trial.

The vaccine candidate was 93.2% effective against VoC/VoI, which represented 82% of the cases, hitting a key exploratory endpoint of the trial.

On top of that, NVX-CoV2372 was also successful at preventing COVID-19 in high-risk populations, defined as individuals aged over age 65, under age 65 with certain comorbidities or those who are frequently exposed to COVID-19.

The vaccine had an efficacy of 91% in these participants, with 62 COVID-19 cases in the placebo group and 13 in the vaccine group.

"PREVENT-19 confirms that NVX-CoV2373 offers a reassuring tolerability and safety profile. [This] data show[s] consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus,” said Gregory M. Glenn, president of research and development, Novavax.

“Our vaccine will be a critical part of the solution to COVID-19 and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the US government,” he added.

Novavax is planning to file the vaccine for regulatory authorisations in Q3, with the company adding that it is on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter.

By the end of the fourth quarter of 2021, Novavax said it is also on track to manufacture 150 million doses per month.

Article by
Lucy Parsons

15th June 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....